Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. On February 17, 2026, the company completed the acquisition of Faeth Therapeutics, a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. This acquisition integrated Faeth's lead asset, PIKTOR, into the company's pipeline. PIKTOR is a proprietary investigational all-oral combination of serabelisib and sapanisertib, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. In connection with the acquisition, the company received $200 million in gross proceeds from a private placement financing, referred to as the 2026 Private Placement. This financing was supported by a syndicate of investors, including B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, and Vivo Capital, to advance PIKTOR through key clinical milestones.